Metallothionein immunoexpression in oral leukoplakia

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 13, Issue 3, 2008, Pages 156-160

  Johann, Aline Cristina Batista Rodrigues ^a   Da Silveira Jr , João Batista ^a   Souto, Giovanna Ribeiro ^a   Horta, Martinho Campolina Rebello ^b   Aguiar, Maria Cássia Ferreira ^a   Mesquita, Ricardo Alves ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Immunohistochemistry; Metallothionein; Oral leukoplakia

Indexed keywords

METALLOTHIONEIN;

ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; DYSPLASIA; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; IMMUNOHISTOCHEMISTRY; LEUKOPLAKIA; MOSAICISM; MOUTH CAVITY; MOUTH MUCOSA; PROTEIN EXPRESSION; RANK SUM TEST; STATISTICAL ANALYSIS;

FEMALE; HUMANS; LEUKOPLAKIA, ORAL; MALE; METALLOTHIONEIN;

EID: 41849117704     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Axéll T, Pindborg JJ, Smith CJ, Van der Waal I. Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med. 1996 Feb;25(2):49-54.
2. Fischer DJ, Epstein JB, Morton TH, Schwartz SM. Interobserver reliability in the histopathologic diagnosis of oral pre-malignant and malignant lesions. J Oral Pathol Med. 2004 Feb;33(2):65-70.
3. Scheifele C, Reichart PA. Is there a natural limit of the transformation rate of oral leukoplakia. Oral Oncol. 2003 Jul;39(5):470-5.
4. Santos-García A, Abad-Hernández MM, Fonseca-Sánchez E, Cruz-Hernández JJ, Bullón-Sopelana A. Proteic expression of p53 and cellular proliferation in oral leukoplakias. Med Oral Patol Oral Cir Bucal. 2005 Jan-Feb;10(1):5-8; 1-5.
5. Chimenos-Küstner E, Font-Costa I, López-López J. Oral cancer risk and molecular markers. Med Oral Patol Oral Cir Bucal. 2004 Nov-Dec;9(5):381-4; 377-80.
6. Warnakulasuriya S. Lack of molecular markers to predict malignant potential of oral precancer. J Pathol. 2000 Mar;190(4):407-9.
7. Takeda T, Sugihara K, Hirayama Y, Hirano M, Tanuma JI, Semba I. Immunohistological evaluation of Ki-67, p63, CK19 and p53 expression in oral epithelial dysplasias. J Oral Pathol Med. 2006 Jul;35(6):369-75.
8. Lee JJ, Hong WK, Hittelman WN, Mao L, Lotan R, Shin DM, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res. 2000 May;6(5):1702-10.
9. Waldron CA, Shafer WG. Leukoplakia revisited. A clinicopathologic study 3256 oral leukoplakias. Cancer. 1975 Oct;36(4):1386-92.
10. Reibel J. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med. 2003;14(1):47-62.
11. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med. 2001 Apr 26;344(17):1323-6.
12. Bouquot JE, Speight PM, Farthing PM. Epithelial dysplasia of the oral mucosa: Diagnostic problems and prognostic features. Curr Diag Pathol 2006;12:11-21.
13. Liu SC, Sauter ER, Clapper ML, Feldman RS, Levin L, Chen SY, et al. Markers of cell proliferation in normal epithelia and dysplastic leukoplakias of the oral cavity. Cancer Epidemiol Biomarkers Prev. 1998 Jul;7(7):597-603.
14. Chattopadhyay A, Ray JG, Caplan DJ. Agnor count as objective marker for dysplastic features in oral leukoplakia. J Oral Pathol Med. 2002 Oct;31(9):512-7.
15. Fan GK, Chen J, Ping F, Geng Y. Immunohistochemical analysis of P57(kip2), p53 and hsp60 expressions in premalignant and malignant oral tissues. Oral Oncol. 2006 Feb;42(2):147-53.
16. Takeda A, Hisada H, Okada S, Mata JE, Ebadi M, Iversen PL. Tumor cell growth is inhibited by suppressing metallothionein-I synthesis. Cancer Lett. 1997 Jun 24;116(2):145-9.
17. Mitropoulos D, Kyroudi-Voulgari A, Theocharis S, Serafetinides E, Moraitis E, Zervas A, et al. Prognostic significance of metallothionein expression in renal cell carcinoma. World J Surg Oncol. 2005 Jan 17;3(1):5.
18. Kägi JH, Schäffer A. Biochemistry of metallothionein. Biochemistry. 1988 Nov 15;27(23):8509-15.
19. Sundelin K, Jadner M, Norberg-Spaak L, Davidsson A, Hellquist HB. Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue. Eur J Cancer. 1997 Oct;33(11):1860-4.
20. Cardoso SV, Barbosa HM, Candellori IM, Loyola AM, Aguiar MC. Prognostic impact of metallothionein on oral squamous cell carcinoma. Virchows Arch. 2002 Aug;441(2):174-8.
21. Gale N, Pilch BZ, Sidransky D, Westra WH, Califano J. Epithelial precursor lesions. In: Barnes L, Eveson JW, Reichart PA, Sidransky D, eds, World Health Organization Classification of tumors. Pathology and Genetics of Head and neck tumours. Lyon: IARC Press; 2005. p. 140-3.
22. Miller RT, Kubier PHT, Reynolds BHT, Henry TB, Turnbow HB. Blocking of Endogenous Avidin-Binding Activity in Immunohistochemistry: The Use of Skim Milk as an Economical and Effective Substitute for Commercial Biotin Solutions. Appl Immunohistochem Mol Morphol 1999;7:63-5.
23. Ayres M, Ayres JR, Ayres DM, Santos AS. Bioestat 3.0: aplicações estatísticas nas áreas das ciências biológicas e médicas. Lithera Maciel, Belém (2003).
24. Cherian MG, Jayasurya A, Bay BH. Metallothioneins in human tumors and potential roles in carcinogenesis. Mutat Res. 2003 Dec 10;533(1-2):201-9.
25. Ioachim E, Assimakopoulos D, Peschos D, Zissi A, Skevas A, Agnantis NJ. Immunohistochemical expression of metallothionein in benign premalignant and malignant epithelium of the larynx: correlation with p53 and proliferative cell nuclear antigen. Pathol Res Pract. 1999;195(12):809-14.
26. Theocharis S, Karkantaris C, Philipides T, Agapitos E, Gika A, Margeli A, et al. Expression of metallothionein in lung carcinoma: correlation with histological type and grade. Histopathology. 2002 Feb;40(2):143-51.
27. Zeng J, Vallee BL, Kägi JH. Zinc transfer from transcription factor IIIA fingers to thionein clusters. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):9984-8.
28. Chubatsu LS, Meneghini R. Metallothionein protects DNA from oxidative damage. Biochem J. 1993 Apr 1;291 (Pt 1):193-8.
29. Ostrakhovitch EA, Olsson PE, Jiang S, Cherian MG. Interaction of metallothionein with tumor suppressor p53 protein. FEBS Lett. 2006 Feb 20;580(5):1235-8.
30. Hainaut P, Milner J. A structural role for metal ions in the "wildtype" conformation of the tumor suppressor protein p53. Cancer Res. 1993 Apr 15;53(8):1739-42.